福泰制药（VRTX）针对1型糖尿病的干细胞疗法Zimislecel（VX-880）展示正面数据。

Core Viewpoint - Vertex Pharmaceuticals (VRTX) has demonstrated positive data for its stem cell therapy Zimislecel (VX-880) targeting Type 1 diabetes [1] Company Summary - Vertex Pharmaceuticals is advancing its stem cell therapy Zimislecel (VX-880) which shows promising results in treating Type 1 diabetes [1] Industry Summary - The development of stem cell therapies for Type 1 diabetes represents a significant advancement in the biotechnology sector, highlighting the potential for innovative treatments in chronic conditions [1]